Ignyta Appoints Dr. Christian V. Kuhlen as General Counsel

SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Dr. Christian V. Kuhlen has been appointed to serve as its General Counsel and Secretary, replacing Matt Onaitis. Since 2007, Dr. Kuhlen served as General Counsel, Vice President and Secretary of Genoptix, Inc., where he led the legal and corporate governance functions from its initial public offering in 2007, through its successful acquisition by Novartis in 2011. Following the completion of Genoptix’s acquisition, Dr. Kuhlen continued to serve the company in these capacities, as well as leading its internal public policy function. Prior to joining Genoptix, Dr. Kuhlen was an attorney in private practice with Cooley LLP from October 2004 to September 2007. Dr. Kuhlen holds a B.S. in Biochemistry and Cell Biology and a B.A. in Economics from the University of California, San Diego, and a J.D. and M.D. from the University of Southern California.

"Chris has extensive legal experience with development-stage and publicly-traded, commercial-stage precision medicine companies, coupled with a strong medical and scientific background that is rare amongst General Counsel," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "We expect that his background in advising on complex business transactions, as well as his years of experience supporting operational teams, will strengthen our management team as we strive to benefit patients with entrectinib and our other cancer precision medicines in development. Speaking on behalf of the team at Ignyta, we also would like to thank Matt for his excellent contributions to Ignyta, and wish him all the best in the next stage of his career."

About Ignyta, Inc.

At Ignyta, we fight cancer – a formidable opponent that manifests as thousands of different molecularly defined diseases and takes away millions of lives globally every year. In this fight, our vision is not just to shrink tumors but to eradicate residual disease – the source of cancer relapse and recurrence – in precisely defined patient populations by 2030. We will work tirelessly to achieve this vision by pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Our Rx efforts are focused on discovering, in-licensing or acquiring, then developing and commercializing, molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Our Dx efforts aim to pair these product candidates with biomarker-based companion diagnostics that are designed to precisely identify, at the molecular level, the patients who are most likely to benefit from the therapies we develop. We believe that only through this integrated Rx/Dx approach can we succeed in this fight.

For more information, please visit: www.ignyta.com.

Forward-Looking Statements:

This press release contains “forward-looking statements” about Ignyta as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements are made as of the date of this press release, and Ignyta assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the company files with the SEC available at www.sec.gov, including without limitation Ignyta's Annual Report on Form 10-K for the year ended December 31, 2015 and subsequent Quarterly Reports on Form 10-Q.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160705005228/en/

Ignyta, Inc.
Jacob Chacko, M.D.
CFO
858-255-5959
[email protected]

Source: Ignyta, Inc.

You May Also Be Interested In

• Elroy Air wins $46M U.S. Army contract for cargo drone system
• Werewolf Therapeutics to merge with Ambros in $150M private placement
• MicroCloud Hologram acquires 140,268 MicroStrategy shares via structured note